drugset / Trial / NCT03563846

Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects

NCT03563846 ↗

Phase 1 Completed 14 enrolled Ritter Pharmaceuticals, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

Randomized, open-label, 2-period, 2-sequence, crossover study to evaluate the effect of a standard meal on the pharmacokinetic (PK) profile of orally administered RP-G28.

Timeline

Start
2018-03-09
Primary completion
2018-04-13
Completion
2018-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject RP-G28 Oligonucleotide (other) 15 g Oral

Indications